Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

34
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
34
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

19
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
19
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

686
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
686
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

936
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
936
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

334
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
334
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

1.1K
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cystic fibrosis liver disease progression in the era of elexacaftor-tezacaftor-ivacaftor.

JHEP reports : innovation in hepatology·2025
Same author

Anti-fibroblast and anti-endothelial cell autoantibodies in pulmonary arterial hypertension (PAH) in patients with connective tissue diseases (CTD).

Rheumatology (Oxford, England)·2025
Same author

Alcohol Rehabilitation Within 3 Months After Alcohol Hepatitis and Survival: A National Analysis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2024
Same author

Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort.

Clinical diabetes and endocrinology·2024
Same author

Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes.

Journal of hepatology·2024
Same author

Histological Characteristics and Management of Hepatitis on Immune Checkpoint Inhibitors: A Retrospective Descriptive Study.

Journal of clinical medicine·2023
Same journal

Urinary Volatile Organic Compound Metabolites Are Associated With MASLD/MASH in Humans and Induce Steatosis in Liver Organoids.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same journal

Hepatic and Cardiovascular Outcomes in Primary Biliary Cholangitis With Metabolic-Dysfunction Associated Steatotic Liver Disease.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same journal

Microtubule-Targeting Drugs Induce Mesenchymal-Epithelial Transition in Hepatic Stellate Cells.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same journal

Systematic Review and Meta-Analysis of Lactulose for the Prevention and Treatment of Hepatic Encephalopathy.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same journal

Adeno-Associated Virus Gene Therapy for Spinal Muscular Atrophy Induces Hepatotoxicity via Cytokine and Macrophage Activation.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same journal

The Changing Etiological Landscape of Liver Cancer in the Era of Metabolic Disease.

Liver international : official journal of the International Association for the Study of the Liver·2026
See all related articles

Related Experiment Video

Updated: Mar 28, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

HCV and the kidney.

Marion Corouge1,2, Anaïs Vallet-Pichard1,2, Stanislas Pol1,2

  • 1Hepatology Department, Université Paris Descartes, Cochin Hospital, APHP, Paris, France.

Liver International : Official Journal of the International Association for the Study of the Liver
|January 5, 2016
PubMed
Summary
This summary is machine-generated.

Chronic hepatitis C (CHC) significantly harms kidney function, increasing mortality in dialysis patients. Oral antiviral therapies, like direct-acting antivirals (DAAs), offer excellent outcomes for CHC patients with advanced chronic kidney disease.

Keywords:
dialysisdirect-acting antiviral drughepatitis Ckidney disease

More Related Videos

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

20.0K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K

Related Experiment Videos

Last Updated: Mar 28, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

20.0K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K

Area of Science:

  • Nephrology
  • Hepatology
  • Virology

Background:

  • Chronic hepatitis C (CHC) is linked to progressive renal deterioration.
  • Advanced chronic kidney disease (CKD) exacerbates hepatitis C virus (HCV) infection and impacts liver health, transplantation outcomes, and patient survival.
  • HCV-infected dialysis patients face higher mortality rates compared to uninfected patients or HCV-infected kidney recipients.

Purpose of the Study:

  • To highlight the critical association between CHC and renal impairment.
  • To emphasize the necessity of oral antiviral treatments for CKD patients with HCV.
  • To advocate for prioritized treatment access for specific CKD patient groups.

Main Methods:

  • Review of existing literature on CHC, CKD, and HCV outcomes.
  • Analysis of mortality data comparing different patient cohorts (dialysis, kidney recipients).
  • Evaluation of current treatment guidelines and outcomes for direct-acting antiviral (DAA) therapies in CKD.

Main Results:

  • Renal impairment, particularly stage 4-5 CKD, increases HCV prevalence and negatively affects liver health and transplant outcomes.
  • HCV-infected dialysis patients exhibit significantly higher mortality.
  • DAA treatment in late-stage CKD patients demonstrates excellent efficacy, comparable to the general population.

Conclusions:

  • Oral antiviral therapies are crucial for managing HCV in patients with CKD.
  • Patients with stage 4-5 CKD, including dialysis patients and kidney recipients, require prioritized access to DAAs.
  • Further research is needed to refine DAA treatment protocols for CKD patients, focusing on dosage adjustments and drug interactions.